Evidence map›Paper›PMID 35144724›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022

Early chains of transmission of COVID-19 in France, January to March 2020.

Juliette Paireau, Alexandra Mailles, Catherine Eisenhauer, Franck de Laval, François Delon, Paolo Bosetti, Henrik Salje, Valérie Pontiès, Simon Cauchemez

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy.International journal of environmental research and public health · 2022
    Article
  9. Article
  10. Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juliette PaireauMathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, CNRS UMR2000, Paris, France.
Alexandra MaillesSanté publique France, French National Public Health Agency, Saint-Maurice, France.
Catherine EisenhauerMathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, CNRS UMR2000, Paris, France.
Franck de LavalSSA, Service de Santé des Armées, CESPA, French Armed Forces Center for Epidemiology and Public Health, Marseille, France.
François DelonSSA, Service de Santé des Armées, CESPA, French Armed Forces Center for Epidemiology and Public Health, Marseille, France.
Paolo BosettiMathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, CNRS UMR2000, Paris, France.
Henrik SaljeMathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, CNRS UMR2000, Paris, France.
Valérie PontièsSanté publique France, Hauts-de-France Regional Office, Lille, France.
Simon CauchemezMathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université de Paris, CNRS UMR2000, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionSARS-CoV-2, the virus that causes COVID-19, has spread rapidly worldwide. In January 2020, a surveillance system was implemented in France for early detection of cases and their contacts to help limit secondary transmissions.AimTo use contact-tracing data collected during the initial phase of the COVID-19 pandemic to better characterise SARS-CoV-2 transmission.MethodsWe analysed data collected during contact tracing and retrospective epidemiological investigations in France from 24 January to 30 March 2020. We assessed the secondary clinical attack rate and characterised the risk of a contact becoming a case. We described chains of transmission and estimated key parameters of spread.ResultsDuring the study period, 6,082 contacts of 735 confirmed cases were traced. The overall secondary clinical attack rate was 4.1% (95% confidence interval (CI): 3.6-4.6), increasing with age of index case and contact. Compared with co-workers/friends, family contacts were at higher risk of becoming cases (adjusted odds ratio (AOR): 2.1, 95% CI: 1.4-3.0) and nosocomial contacts were at lower risk (AOR: 0.3, 95% CI: 0.1-0.7). Of 328 infector/infectee pairs, 49% were family members. The distribution of secondary cases was highly over-dispersed: 80% of secondary cases were caused by 10% of cases. The mean serial interval was 5.1 days (interquartile range (IQR): 2-8 days) in contact tracing pairs, where late transmission events may be censored, and 6.8 (3-8) days in pairs investigated retrospectively.ConclusionThis study increases knowledge of SARS-CoV-2 transmission, including the importance of superspreading events during the onset of the pandemic.

Indexed as

COVID-19Contact TracingHumansPandemicsRetrospective StudiesSARS-CoV-2clustercontact tracingSARS-CoV-2secondary clinical attack ratesuperspreadingtransmission

Identifiers

PMID35144724
PMCPMC8832523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.